Heavy Cannabis Users: Subjective High and Psychomotor Tests Did Not Move Together

Heavy cannabis users can report a substantial high while showing comparatively modest changes on selected psychomotor tests. That dissociation does not establish unimpaired driving or a universal tolerance exemption.

What the experiment measured

Ten chronic cannabis smokers completed controlled smoking sessions with serial whole-blood THC measurements and subjective, physiological and psychomotor assessments. Nine participants were men. The study involved a specified cigarette, rather than today’s entire range of cannabis products.

The researchers compared the timing of reported effects with concentrations collected at the same assessment points. Whole blood was the stated matrix; those values should not be substituted with plasma concentrations from unrelated experiments.

Positive and null responses coexisted

Smoking significantly increased ratings including high, good drug effect, stoned and sedation. Anxiety and restlessness did not significantly change. The authors characterized psychomotor changes as modest relative to the robust subjective and cardiovascular responses.

A null anxiety rating therefore did not mean no intoxication, and a modest task effect did not erase a strong reported high. Different endpoints capture different aspects of response.

Timing complicated the concentration relationship

Blood THC declined rapidly while subjective effects persisted. Mean concentration–effect plots formed counterclockwise hysteresis loops, and individual plots varied substantially.

The same concentration on different portions of a time course can therefore coexist with different effects. A group-average loop does not provide an exact individual reconstruction of time since smoking or functional condition.

How far tolerance evidence travels

The small, selected group limits generalization to occasional users, women and other dosing patterns. Selected laboratory tasks are not equivalent to a complete on-road assessment or collision-risk estimate.

The study supports separating use history, subjective experience, task performance and measured concentration. It does not establish that heavy users are always unaffected, or that subjective high alone supplies an objective measure of every ability relevant to driving.

For context, see our discussion of THC concentrations and the separate question of impairment.

Primary research

David M. Schwope and colleagues. Psychomotor Performance, Subjective and Physiological Effects and Whole Blood Δ9-Tetrahydrocannabinol Concentrations in Heavy, Chronic Cannabis Smokers Following Acute Smoked Cannabis. Journal of Analytical Toxicology (2012). DOI: 10.1093/jat/bks044.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

A Higher Edible Dose Did Not Produce a Higher Mean Blood THC Peak in Every Group

A 50 mg edible THC dose did not produce a higher mean whole-blood THC peak than 25 mg in a small between-group study. That observation does not show reversed absorption or make blood concentration a reliable dose calculator. Only six people received each dose Healthy adults without recent cannabis use…

Spread the love

Read Article: A Higher Edible Dose Did Not Produce a Higher Mean Blood THC Peak in Every Group

Oral-Fluid Parent Cannabinoids and Metabolites Followed Different Route Patterns

An oral-fluid THC peak immediately after cannabis use can reflect material deposited in the mouth rather than peak systemic exposure. A controlled comparison of smoked, vaporized and edible cannabis found different route patterns for parent cannabinoids and metabolites. Within-person route comparisons Eleven frequent and nine occasional cannabis smokers completed a…

Spread the love

Read Article: Oral-Fluid Parent Cannabinoids and Metabolites Followed Different Route Patterns

Transdermal CBD’s Open-Label Seizure Improvement Did Not Reverse Its Blinded Null Result

Transdermal CBD did not significantly reduce seizure frequency compared with placebo during a blinded adult focal-epilepsy trial. Improvement during the later open-label extension answered a different question and did not overturn that randomized comparison. A daily-dose distinction clarified by correction The trial randomized 188 adults to transdermal CBD or placebo….

Spread the love

Read Article: Transdermal CBD’s Open-Label Seizure Improvement Did Not Reverse Its Blinded Null Result

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us